Why CAR T cell therapy fails in renal cell carcinoma - Takeaways - MDSpire

Why CAR T cell therapy fails in renal cell carcinoma

  • By

  • Hua-jun Zhang

  • Lv-zhou Han

  • Xiang Zhang

  • Yang-lu Ge

  • June 11, 2026

  • 0 min

Share

  • 1

    CAR T cell therapy has shown limited clinical efficacy in renal cell carcinoma despite the presence of targetable tumor antigens.

  • 2

    Challenges in CAR T therapy for RCC include limited tumor trafficking, rapid functional decline, and poor intratumoral persistence.

  • 3

    Antigen recognition alone does not ensure therapeutic success in RCC, highlighting a systemic mismatch with the renal tumor ecosystem.

  • 4

    Biological barriers to CAR T efficacy in RCC include immune exclusion, metabolic competition, and environmental support insufficiency.

  • 5

    A shift towards RCC-adapted cellular therapies may be necessary to enhance tumor homing and improve T cell function.

Original Source(s)

Why CAR T cell therapy fails in renal cell carcinoma

  • by Hua-jun Zhang, Lv-zhou Han, Xiang Zhang, Yang-lu Ge

  • June 11, 2026

Related Content

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes

Spatial immune archetypes in gastric and colorectal cancer: a proposed conceptual framework for immunotherapy resistance and therapeutic remodeling

Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer